scholarly journals Epstein-Barr Virus (EBV) Genome and Expression in Breast Cancer Tissue: Effect of EBV Infection of Breast Cancer Cells on Resistance to Paclitaxel (Taxol)

2006 ◽  
Vol 80 (2) ◽  
pp. 845-853 ◽  
Author(s):  
Hratch Arbach ◽  
Viktor Viglasky ◽  
Florence Lefeu ◽  
Jean-Marc Guinebretière ◽  
Vanessa Ramirez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Tumor Cells ◽  
Breast Cancer Cells ◽  
Epstein Barr Virus ◽  
Breast Cancer Tissue ◽  
Cancer Tissue ◽  
Barr Virus ◽  
Ebv Infection ◽  
Epstein Barr

ABSTRACT The Epstein-Barr virus (EBV) has been detected in subsets of breast cancers. In order to elaborate on these observations, we quantified by real-time PCR (Q-PCR) the EBV genome in biopsy specimens of breast cancer tissue as well as in tumor cells isolated by microdissection. Our findings show that EBV genomes can be detected by Q-PCR in about half of tumor specimens, usually in low copy numbers. However, we also found that the viral load is highly variable from tumor to tumor. Moreover, EBV genomes are heterogeneously distributed in morphologically identical tumor cells, with some clusters of isolated tumor cells containing relatively high genome numbers while other tumor cells isolated from the same specimen may be negative for EBV DNA. Using reverse transcription-PCR, we detected EBV gene transcripts: EBNA-1 in almost all of the EBV-positive tumors and RNA of the EBV oncoprotein LMP-1 in a smaller subset of the tissues analyzed. Moreover, BARF-1 RNA was detected in half of the cases studied. Furthermore, we observed that in vitro EBV infection of breast carcinoma cells confers resistance to paclitaxel (taxol) and provokes overexpression of a multidrug resistance gene (MDR1). Consequently, even if a small number of breast cancer cells are EBV infected, the impact of EBV infection on the efficiency of anticancer treatment might be of importance.

scholarly journals Dysregulation of HER2/HER3 Signaling Axis in Epstein-Barr Virus-Infected Breast Carcinoma Cells

2007 ◽  
Vol 81 (11) ◽  
pp. 5705-5713 ◽  
Author(s):  
Jiun-Han Lin ◽  
Ching-Hwa Tsai ◽  
Jan-Show Chu ◽  
Jeou-Yuan Chen ◽  
Kenzo Takada ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Epstein Barr Virus ◽  
Soft Agar ◽  
Signaling Cascades ◽  
Barr Virus ◽  
Ebv Infection ◽  
Epstein Barr ◽  
Tumorigenic Activity

ABSTRACT The role of Epstein-Barr virus (EBV) in the pathogenesis of breast cancer has been of long-standing interest to the field. Breast epithelial cells can be infected by EBV through direct contact with EBV-bearing lymphoblastoid cells, and EBV infection has recently been shown to confer breast cancer cells an increased resistance to chemotherapeutic drugs. In this study, we established EBV-infected breast cancer MCF7 and BT474 cells and demonstrated that EBV infection promotes tumorigenic activity of breast cancer cells. Firstly, we showed that the EBV-infected MCF7-A and BT474-A cells exhibited increased anchorage-independent growth in soft agar. The increased colony formation capacity in soft agar was associated with increased expression and activation of HER2/HER3 signaling cascades, as evidenced by the findings that the treatment of HER2 antibody trastuzumab (Herceptin), phosphatidylinositol 3-kinase inhibitor, or MEK inhibitor completely abolished the tumorigenic capacity. In the EBV-infected breast cancer cells, the expression of EBV latency genes including EBNA1, EBER1, and BARF0 was detected. We next showed that BARF0 alone was sufficient to efficiently up-regulate HER2/HER3 expression and promoted tumorigenic activity in MCF7 and BT474 cells by the use of both overexpression and small interfering RNA knock-down. Collectively, we demonstrated that EBV-encoded BARF0 promotes the tumorigenic activity of breast cancer cells through activation of HER2/HER3 signaling cascades.

Epstein–Barr virus is seldom found in mammary epithelium of breast cancer tissue using in situ molecular methods

2011 ◽  
Vol 132 (1) ◽  
pp. 267-274 ◽  
Author(s):  
Kimberly Baltzell ◽  
Gertrude C. Buehring ◽  
Savitri Krishnamurthy ◽  
Henry Kuerer ◽  
Hua Min Shen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epstein Barr Virus ◽  
Mammary Epithelium ◽  
Breast Cancer Tissue ◽  
Molecular Methods ◽  
Cancer Tissue ◽  
Barr Virus ◽  
Epstein Barr

scholarly journals Signalling mechanisms regulating phenotypic changes in breast cancer cells

2015 ◽  
Vol 35 (2) ◽  
Author(s):  
Natalia Volinsky ◽  
Cormac J. McCarthy ◽  
Alex von Kriegsheim ◽  
Nina Saban ◽  
Mariko Okada-Hatakeyama ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Cell Line ◽  
Breast Cancer Cells ◽  
Breast Cancer Tissue ◽  
Cancer Tissue ◽  
Phenotypic Changes ◽  
Model Cell ◽  
Accumulation Of Lipids

Excessive production and accumulation of lipids is often observed in breast cancer tissue. In the current study, we investigate signalling mechanisms regulating this process using a model cell line.

scholarly journals ”BIK/NBK Gene Expression as a Possible Marker of Circulating Breast Cancer Cells in Blood“

2011 ◽  
Vol 4 (1) ◽  
pp. 8-14
Author(s):  
E. Lopez-Munoz ◽  
N. Garcia-Hernandez ◽  
R. I. Penaloza-Espinosa ◽  
M. E. Gomez-Del Toro ◽  
G. Zarco-Espinosa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Cancer Cells ◽  
Therapeutic Target ◽  
Breast Cancer Cells ◽  
Expression Profiles ◽  
Gene Expression Profiles ◽  
Breast Cancer Tissue ◽  
Cancer Tissue ◽  
Mrna Gene

The detection of circulating breast cancer cells in blood could be of special interest as an indicator of diagnosis and prognosis, and for the selection of treatment. In a previous report, our research group determined gene expression profiles in samples of breast cancer tissue, identifying over-expression of the BIK/NBK mRNA gene in 90% of the analyzed samples. In this paper, we analyze the BIK/NBK gene expression as a possible biomarker of circulating breast cancer cells in blood. We demonstrate that the BIK/NBK gene expression is not a significant biomarker in the detection of circulating breast cancer cells in the blood of women with breast cancer. Several studies have evaluated the regulation of apoptosis by estrogens in breast cancer cells, demonstrating the importance of BIK/NBK protein, in estrogen-regulated breast cancer cell apoptosis, which suggests that the regulation of its expression may be an important therapeutic target or strategy in the management of cancer, and, although we did not find statistically significant differences among the patient groups to demonstrate that BIK/NBK gene expression is a biomarker of circulating breast cancer cells in blood, we consider it necessary to continue the study of this gene in breast cancer tissue and its role in the development and progression of breast cancer, its prognostic value, and its potential use as therapeutic target.

scholarly journals MiR-92b-3p Inhibits Proliferation of HER2-Positive Breast Cancer Cell by Targeting circCDYL

2021 ◽  
Vol 9 ◽  
Author(s):  
Gehao Liang ◽  
Yun Ling ◽  
Qun Lin ◽  
Yu Shi ◽  
Qing Luo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Proliferation ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Biological Function ◽  
Breast Cancer Tissue ◽  
Cancer Tissue ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Over Expression

ObjectivesCircular RNA (circRNA) is a novel class of RNA, which exhibits powerful biological function in regulating cellular fate of various tumors. Previously, we had demonstrated that over-expression of circRNA circCDYL promoted progression of HER2-negative (HER2–) breast cancer via miR-1275-ULK1/ATG7-autophagic axis. However, the role of circCDYL in HER2-positive (HER2+) breast cancer, in particular its role in modulating cell proliferation, one of the most important characteristics of cellular fate, is unclear.Materials and methodsqRT-PCR and in situ hybridization analyses were performed to examine the expression of circCDYL and miR-92b-3p in breast cancer tissues or cell lines. The biological function of circCDYL and miR-92b-3p were assessed by plate colony formation and cell viability assays and orthotopic animal models. In mechanistic study, circRNAs pull-down, RNA immunoprecipitation, dual luciferase report, western blot, immunohistochemical and immunofluorescence staining assays were performed.ResultsCircCDYL was high-expressed in HER2+ breast cancer tissue, similar with that in HER2– breast cancer tissue. Silencing HER2 gene had no effect on expression of circCDYL in HER2+ breast cancer cells. Over-expression of circCDYL promoted proliferation of HER2+ breast cancer cells but not through miR-1275-ULK1/ATG7-autophagic axis. CircRNA pull down and miRNA deep-sequencing demonstrated the binding of miR-92b-3p and circCDYL. Interestingly, circCDYL did not act as miR-92b-3p sponge, but was degraded in miR-92b-3p-dependent silencing manner. Clinically, expression of circCDYL and miR-92b-3p was associated with clinical outcome of HER2+ breast cancer patients.ConclusionMiR-92b-3p-dependent cleavage of circCDYL was an essential mechanism in regulating cell proliferation of HER2+ breast cancer cells. CircCDYL was proved to be a potential therapeutic target for HER2+ breast cancer, and both circCDYL and miR-92b-3p might be potential biomarkers in predicting clinical outcome of HER2+ breast cancer patients.

scholarly journals Molecular Epidemiology of Epstein-Barr Virus in Women Breast Cancer in Congo Brazzaville

2021 ◽  
Vol 11 (11) ◽  
pp. 180-190
Author(s):  
Dimitry Moudiongui Mboungou Malanda ◽  
Anicet Luc Magloire Boumba ◽  
Fabien Gaël Mouamba
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Tissue ◽  
Cancer Tissue ◽  
Barr Virus ◽  
Significant Difference ◽  
Ebv Dna ◽  
Epstein Barr ◽  
The Republic ◽  
Congo Brazzaville ◽  
Formalin Fixed

Introduction: the Epstein Barr virus is one of the very first oncogenic viruses to be identified as responsible for human malignancies. Its role as an etiological agent of breast cancer remains controversial, however, despite the growing molecular evidence. The aim of this study was detected the presence of EBV DNA in patients with breast cancer in the Republic of Congo. Methods: The study was conducted on 90 samples of formalin fixed and paraffin-embedded tissue blocks (FFPE) from breast cancer tissue. The immunohistochemistry technique was used to test for the expression of the LMP1 antibody and DNA was extracted from all blocks of formalin-fixed and paraffin-embedded breast cancer tissue (FFPE) to detect presence of EBV 1 DNA by real-time polymerase chain reaction (PCR). Results: EBV was detected in 12.33% (12/90) of formalin-fixed, paraffin-embedded (FFPE) breast cancer tissue blocks. All formalin-fixed, paraffin-embedded (FFPE) breast cancer tissue blocks with positive EBV DNA were high tumor grades (II and III). Overall EBV infection with clinicopathological features of breast cancer cases showed no significant difference (P>0.05). However, a statistically significant difference was observed between EBV infection and histological types (P=0.04). Conclusion: Our results provide evidence for the presence of EBV DNA in female breast cancer in Congo Brazzaville. However, this evidence is substantial but inconclusive for the involvement of viruses in the development of breast cancer. Therefore, future investigations will be needed to elucidate the exact role of EBV in breast cancer in women in the Republic of Congo. Key words: EBV, breast cancer, women, Congo Brazzaville.

Epstein–Barr virus and risk of breast cancer: a systematic review and meta-analysis

2019 ◽  
Vol 15 (24) ◽  
pp. 2873-2885 ◽  
Author(s):  
Mohammad Farahmand ◽  
Seyed Hamidreza Monavari ◽  
Zabihollah Shoja ◽  
Hadi Ghaffari ◽  
Mehdi Tavakoli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epstein Barr Virus ◽  
Potential Role ◽  
Meta Analysis ◽  
Case Control ◽  
Case Control Studies ◽  
Barr Virus ◽  
Ebv Infection ◽  
Epstein Barr

Despite the numerous publications regarding the role of Epstein–Barr virus (EBV) in breast cancer development, the topic has still remained controversial. The aim of the meta-analysis was to estimate the overall prevalence of EBV in the breast cancer population, and to investigate the association between EBV and breast cancer risk. The overall prevalence of EBV was calculated 26.37% (95% CI: 22–31%) from the 44 included studies. Meta-analysis of 30 case–control studies showed that the pooled association between EBV and risk of breast cancer is odds ratio 4.74 (95% CI: 2.92–7.69; Z = 6.30; p < 0.0001). Our analyses indicate a strong statistical relationship between EBV infection and risk of breast cancer, suggesting a potential role of EBV infection in the development of breast cancer.

Sign in / Sign up

Export Citation Format

Share Document